Bond Biosciences, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.
Our clinical lead, BBI-001, was designed to be a safe, convenient, and effective treatment for sufferers of iron overload associated with Hereditary Hemochromatosis. By binding dietary iron to inhibit absorption, BBI-001 is designed to prevent the potentially serious consequences of unmanaged iron overload resulting from hemochromatosis, such as liver disease, heart problems, diabetes, elevated cancer risk, and significant joint pain.
Our clinical lead, BBI-001, was designed to be a safe, convenient, and effective treatment for sufferers of iron overload associated with Hereditary Hemochromatosis. By binding dietary iron to inhibit absorption, BBI-001 is designed to prevent the potentially serious consequences of unmanaged iron overload resulting from hemochromatosis, such as liver disease, heart problems, diabetes, elevated cancer risk, and significant joint pain.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
MO
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
BBI-001
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
